DIT Acquires Lifeline PICC

Dynamic Infusion Therapy, LLC (“DIT”), a longstanding provider of outsourced vascular access services, is excited to announce the acquisition of Lifeline PICC in Tulsa, OK. Under the leadership of Kathy Wagner, RN, CRNI, VA-BC, the founder and owner of the company, Lifeline PICC has been providing high quality services and supplies for peripherally inserted central catheters (PICCs) at healthcare organizations across the Tulsa area for the past 8 years.

According to Wagner, “DIT was a natural choice to support the continued growth of my business.  I have full confidence in their ability to carry on the legacy of what we’ve been building over the years.”  Wagner will be joining the leadership team of DIT and will oversee the integration of her company during the next few months.

Peter Harris, President & Chief Executive Officer of DIT, commented that “bringing Lifeline PICC and Kathy into our growing family will contribute to our continued success.  Our nurses already insert vascular access devices on-demand for about 100,000 patients a year.  Adding the Tulsa market will expand our geographic footprint further allowing us to make a difference to the patients and healthcare organizations there.”

In connection with the transaction, DIT welcomed the experienced Lifeline PICC nurses to its team and will be providing services to several prominent healthcare clients in the Tulsa area. Both companies share a clinical model that focuses on lowering customer costs while providing better patient outcomes.

More patients receive PICCs from DIT than any other outsourced provider in the U.S., and DIT’s nurses have consistently achieved an overall success rate greater than 99%. The Joint Commission first accredited DIT a decade ago and has awarded DIT its Gold Seal of Approval.  In early 2021, RiverGlade Capital, a healthcare-focused private equity firm, partnered with DIT to build on its reputation for clinical excellence.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”